传统PCI
拉回
心脏病学
支架
经皮冠状动脉介入治疗
医学
内科学
生物医学工程
几何学
数学
心肌梗塞
作者
Pruthvi C. Revaiah,Kotaro Miyashita,Tsung-Ying Tsai,Retesh Bajaj,Nozomi Kotoku,Akihiro Tobe,Takashi Muramatsu,Kengo Tanabe,Ken Kozuma,Yukio Ozaki,Scot Garg,Shengxian Tu,Jouke Dijkstra,Christos V. Bourantas,Yoshinobu Onuma,Patrick W. Serruys
标识
DOI:10.1093/ehjimp/qyaf017
摘要
Abstract Aims Segmental pressure gradients post-percutaneous coronary intervention (PCI) can detect residual disease and optimization targets. Ultrasonic flow ratio (UFR) or optical flow ratio (OFR) offer simultaneous physiological and morphological assessment using a single imaging catheter. This study evaluated the utility of UFR and OFR in identifying residual disease post-PCI. Methods and results The study include patients from the Acetyl Salicylic Elimination Trial JAPAN Pilot study with complete intravascular imaging pullback data, where UFR or OFR was obtained post-PCI. Anatomical focal lesions distal and proximal to the stent were analysed in segments ≥5 mm long. UFR or OFR virtual pullback curves assessed intra-stent pressure gradients, defining physiological focal or diffuse by segmental pressure drops ≥0.05 over lengths <10 or ≥10 mm, respectively. The median post-PCI UFR/OFR was 0.93 (0.88–0.96) with 35.4% (69/195) vessels having a UFR/OFR < 0.91. There were significantly more focal lesions, both anatomical and physiological, proximal and distal to the stent in vessels with UFR/OFR < 0.91 compared with those ≥0.91. Agreement between anatomical and physiological focal lesions was moderate proximally (kappa = 0.553, P < 0.001) and fair distally (kappa = 0.219, P = 0.002). The in-stent gradient poorly predicted significant stent under-expansion. However, the virtual fractional flow reserve gradient performed well in detecting proximal or distal focal disease (area under the curve = 0.835 and 0.877, respectively). Conclusion UFR/OFR effectively identifies sub-optimal vessel physiology post-PCI and locates precise anatomical issues, validated by intravascular imaging. Trial registration The ASET JAPAN ClinicalTrials.gov reference: NCT05117866
科研通智能强力驱动
Strongly Powered by AbleSci AI